EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences

ZUG, Switzerland — Galderma (SIX: GALD), the pure-play dermatology category leader, will present 19 abstracts and deliver a broad scientific education program at the 2026 European Academy of Dermatology and Venereology (EADV) Congress. Through these activities, Galderma will showcase how it continues to advance its pipeline and the science of dermatology, deepening understanding of biological and quality-of-life factors, while driving innovation in targeted treatments, skin longevity and evidence-based care.

A welcome email is on its way. If you don't see it, please check your junk folder.

“At Galderma, we recognize that advancing dermatology means not only addressing the needs of patients living with common chronic skin conditions, such as atopic dermatitis and acne, but also anticipating the trends that will shape the future of skin health. Our presence at EADV demonstrates our unique ability to achieve this, with new data spanning both established areas of unmet need and emerging fields such as skin longevity, helping drive innovation and meaningful outcomes for patients today and in the years to come.”

Galderma will present new data to EADV attendees to further advance understanding of atopic dermatitis and prurigo nodularis.

Highlights include an oral presentation on the safety and efficacy data from the ARCADIA open-label long-term extension study in adults and adolescents with moderate-to-severe atopic dermatitis, at 152 weeks. 1 It will take place on Thursday, October 1, from 10:45-10:55 AM CET in Hall N. A second oral presentation will examine how itch, skin lesion severity, and conversely, treatment with Nemluvio impact sleep disturbance in patients with atopic dermatitis and prurigo nodularis, and will take place on Thursday, October 1, from 11:15-11:25 AM CET in Hall N. 2 Additional presentations will quantify the impact of itch and skin lesion severity on quality of life in atopic dermatitis and evaluate the long-term safety profile of Nemluvio over two years across the ARCADIA and OLYMPIA extension studies. An exploration of new real-world evidence characterizing patients with atopic dermatitis and prurigo nodularis receiving advanced systemic therapies, alongside a data-driven conceptual disease model designed to deepen understanding of disease burden and outcomes in prurigo nodularis, will also be presented at the congress. 3-7 Galderma will also host a symposium titled “Advancing treatment outcomes in atopic dermatitis and prurigo nodularis: Targeting the IL-31 neuroimmune pathways,” on Friday, October 2, from 1:00-2:00 PM CET in Hall C, Level 2. Featuring experts Dr. Sarina Elmariah, Dr. Andrew Pink, and Prof.